Wakefield Asset Management LLLP Sells 177 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Wakefield Asset Management LLLP trimmed its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 1.2% in the second quarter, according to its most recent filing with the SEC. The firm owned 13,986 shares of the specialty pharmaceutical company’s stock after selling 177 shares during the period. Wakefield Asset Management LLLP owned approximately 0.07% of ANI Pharmaceuticals worth $891,000 as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in ANIP. Vanguard Group Inc. increased its holdings in shares of ANI Pharmaceuticals by 1.4% during the first quarter. Vanguard Group Inc. now owns 1,306,432 shares of the specialty pharmaceutical company’s stock worth $90,314,000 after buying an additional 17,460 shares in the last quarter. Rubric Capital Management LP increased its stake in shares of ANI Pharmaceuticals by 32.8% in the fourth quarter. Rubric Capital Management LP now owns 1,125,000 shares of the specialty pharmaceutical company’s stock valued at $62,032,000 after buying an additional 277,989 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in ANI Pharmaceuticals by 6.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 591,731 shares of the specialty pharmaceutical company’s stock worth $32,628,000 after acquiring an additional 33,359 shares during the last quarter. Global Alpha Capital Management Ltd. lifted its position in shares of ANI Pharmaceuticals by 10.8% during the fourth quarter. Global Alpha Capital Management Ltd. now owns 582,428 shares of the specialty pharmaceutical company’s stock worth $32,115,000 after purchasing an additional 56,900 shares in the last quarter. Finally, Ranger Investment Management L.P. lifted its position in shares of ANI Pharmaceuticals by 1.8% during the fourth quarter. Ranger Investment Management L.P. now owns 434,617 shares of the specialty pharmaceutical company’s stock worth $23,965,000 after purchasing an additional 7,769 shares in the last quarter. 76.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on ANIP. HC Wainwright reiterated a “buy” rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Wednesday, August 7th. StockNews.com cut shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Truist Financial cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 7th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, ANI Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $82.75.

Insider Activity at ANI Pharmaceuticals

In other news, COO Muthusamy Shanmugam sold 20,000 shares of the business’s stock in a transaction that occurred on Friday, June 21st. The stock was sold at an average price of $58.90, for a total transaction of $1,178,000.00. Following the completion of the sale, the chief operating officer now owns 682,620 shares in the company, valued at $40,206,318. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders sold 66,007 shares of company stock valued at $4,091,535 in the last three months. Corporate insiders own 12.70% of the company’s stock.

ANI Pharmaceuticals Stock Down 0.4 %

Shares of ANIP stock opened at $60.51 on Friday. The company has a market capitalization of $1.27 billion, a price-to-earnings ratio of 37.82 and a beta of 0.75. The company has a quick ratio of 3.07, a current ratio of 3.97 and a debt-to-equity ratio of 0.62. ANI Pharmaceuticals, Inc. has a 12-month low of $48.20 and a 12-month high of $70.81. The firm has a fifty day moving average of $61.92 and a 200-day moving average of $63.95.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share for the quarter, beating the consensus estimate of $0.95 by $0.07. The company had revenue of $138.00 million during the quarter, compared to analyst estimates of $129.09 million. ANI Pharmaceuticals had a net margin of 5.01% and a return on equity of 15.64%. ANI Pharmaceuticals’s revenue for the quarter was up 18.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.06 EPS. As a group, equities research analysts predict that ANI Pharmaceuticals, Inc. will post 3.5 earnings per share for the current fiscal year.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.